JP2025500404A - 新規オーリスタチン類似体およびその免疫複合体 - Google Patents

新規オーリスタチン類似体およびその免疫複合体 Download PDF

Info

Publication number
JP2025500404A
JP2025500404A JP2024537875A JP2024537875A JP2025500404A JP 2025500404 A JP2025500404 A JP 2025500404A JP 2024537875 A JP2024537875 A JP 2024537875A JP 2024537875 A JP2024537875 A JP 2024537875A JP 2025500404 A JP2025500404 A JP 2025500404A
Authority
JP
Japan
Prior art keywords
compound
formula
structural formula
antibody
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500404A5 (cg-RX-API-DMAC7.html
Inventor
ホイ リィ,リチャード
ジュン リー,ドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adcentrx Therapeutics Inc
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of JP2025500404A publication Critical patent/JP2025500404A/ja
Publication of JP2025500404A5 publication Critical patent/JP2025500404A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024537875A 2021-12-23 2022-12-21 新規オーリスタチン類似体およびその免疫複合体 Pending JP2025500404A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293583P 2021-12-23 2021-12-23
US63/293,583 2021-12-23
PCT/US2022/053738 WO2023122228A1 (en) 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof

Publications (2)

Publication Number Publication Date
JP2025500404A true JP2025500404A (ja) 2025-01-09
JP2025500404A5 JP2025500404A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=86903604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537875A Pending JP2025500404A (ja) 2021-12-23 2022-12-21 新規オーリスタチン類似体およびその免疫複合体

Country Status (10)

Country Link
US (1) US20250049937A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453000A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500404A (cg-RX-API-DMAC7.html)
KR (1) KR20240152826A (cg-RX-API-DMAC7.html)
CN (1) CN118829645A (cg-RX-API-DMAC7.html)
AU (1) AU2022422015A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241878A1 (cg-RX-API-DMAC7.html)
IL (1) IL313784A (cg-RX-API-DMAC7.html)
TW (1) TW202328162A (cg-RX-API-DMAC7.html)
WO (1) WO2023122228A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
US9884817B2 (en) * 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Also Published As

Publication number Publication date
EP4453000A4 (en) 2025-12-24
AU2022422015A1 (en) 2024-07-04
WO2023122228A1 (en) 2023-06-29
TW202328162A (zh) 2023-07-16
CN118829645A (zh) 2024-10-22
US20250049937A1 (en) 2025-02-13
KR20240152826A (ko) 2024-10-22
CA3241878A1 (en) 2023-06-29
IL313784A (en) 2024-08-01
EP4453000A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
US20260027226A1 (en) Antibody-drug conjugates
CA3027178A1 (en) Anti-egfr antibody drug conjugates
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
TW202313122A (zh) 與ror1和b7-h3結合抗體-藥物偶聯物及其用途
JP7631329B2 (ja) リン脂質-フラバグリン抱合体及び標的化されたがん治療のためのリン脂質-フラバグリン抱合体の使用方法
TW202400266A (zh) 配體藥物偶聯物及其應用
EP4453000A1 (en) Novel auristatin analogs and immunoconjugates thereof
TW202608866A (zh) 包含sting促效劑之抗體藥物結合物及其用途
JP2024540402A (ja) 新規オーリスタチン類似体およびその免疫複合体
WO2025149667A1 (en) Antibody drug conjugates and uses thereof
KR20250049520A (ko) 인간 trop2에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도
EP4471005A1 (en) Conjugate and use thereof
HK40117241A (en) Novel auristatin analogs and immunoconjugates thereof
HK40115429A (en) Novel auristatin analogs and immunoconjugates thereof
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251222